| 000 | 01743 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516203143.0 | ||
| 264 | 0 | _c20140731 | |
| 008 | 201407s 0 0 eng d | ||
| 022 | _a1365-2141 | ||
| 024 | 7 |
_a10.1111/bjh.12835 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAbdulkadyrov, Kudrat M | |
| 245 | 0 | 0 |
_aSotatercept in patients with osteolytic lesions of multiple myeloma. _h[electronic resource] |
| 260 |
_bBritish journal of haematology _cJun 2014 |
||
| 300 |
_a814-23 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 | _aBiomarkers |
| 650 | 0 | 4 | _aBone Density |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunologic Factors _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Myeloma _xcomplications |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aOsteogenesis |
| 650 | 0 | 4 |
_aOsteolysis _xetiology |
| 650 | 0 | 4 |
_aRecombinant Fusion Proteins _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aSalogub, Galina N | |
| 700 | 1 | _aKhuazheva, Nuriet K | |
| 700 | 1 | _aSherman, Matthew L | |
| 700 | 1 | _aLaadem, Abderrahmane | |
| 700 | 1 | _aBarger, Rachel | |
| 700 | 1 | _aKnight, Robert | |
| 700 | 1 | _aSrinivasan, Shankar | |
| 700 | 1 | _aTerpos, Evangelos | |
| 773 | 0 |
_tBritish journal of haematology _gvol. 165 _gno. 6 _gp. 814-23 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/bjh.12835 _zAvailable from publisher's website |
| 999 |
_c23659091 _d23659091 |
||